Recon: Royalty Pharma targets $2B IPO; Judge sides with AbbVie in Humira patent thicket suit

• FDA Misled Senators on China’s Role as Vital US Drug Supplier (Bloomberg)
• Royalty Pharma targets biggest US IPO of the year (Reuters) (STAT) (Endpoints)
• AstraZeneca wins fresh US backing in race for COVID-19 treatment (Reuters)
• AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket' (Law360) (STAT)
• Takeda, Eli Lilly Lose High Court Bid Over Actos RICO Claims (Law360)
• Corning wins US funding for glass vials output for COVID-19 vaccines (Reuters)
• Gilead's remdesivir shows promise in COVID-19 study on monkeys (Reuters)
• Global Blood Therapeutics to seek to expand label for sickle cell treatment (Reuters)
• Special Report: COVID deepens the other opioid crisis - a shortage of hospital painkillers (Reuters)
• Pfizer continues recalls of menopause drug Duavee on faulty packaging concerns (Fierce)

• WHO says pandemic 'far from over' as daily cases hit record high (Reuters)
• Bayer, MSD file heart failure drug vericiguat in EU and Japan (PMLive)
• South Korea's Daewoong Pharmaceutical says anti-parasitic drug effective against coronavirus in animal tests (Reuters)
• After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica (Fierce) (Endpoints)
• Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies (Fierce) (Endpoints)
• NICE rejects Sanofi's Sarclisa in preliminary guidelines (PharmaTimes)
• Lundbeck axes staff in revamp of its R&D (PMLive) (Endpoints)
• Diasorin to appeal Italian court ruling cancelling deal with hospital over COVID test (Reuters)

• ‘We don’t actually have that answer yet’: WHO clarifies comments on asymptomatic spread of Covid-19 (STAT)
• Can a Vaccine for Covid-19 Be Developed in Record Time? (NYTimes)
• COVID-19 vaccines start moving into advanced trials (Nature)
• COVID-19 mAb supplies could fall short of demand (BioCentury)
• Explainer: What are antibody therapies and who is developing them for COVID-19? (Reuters)
• First antibody against COVID-19 spike protein enters phase I (Nature)
• EU actions to support availability of medicines during COVID-19 pandemic (EMA)
• Over half of people tested in Italy's Bergamo have COVID-19 antibodies (Reuters)
• Closing in on all sides: Cuba nears declaring coronavirus victory (Reuters)
• Delhi coronavirus cases set to explode, hospitals running out of beds (Reuters)
• China, scientists dismiss Harvard study suggesting COVID-19 was spreading in Wuhan in August (Reuters)
• Coronavirus (COVID-19) Update: Daily Roundup June 8, 2020 (FDA)

• Females are still routinely left out of biomedical research — and ignored in analyses of data (STAT)
• Developing blockbuster drugs: both nature and nurture (Nature)
• New HRSA Data: 340B Program Reached $29.9 Billion in 2019; Now Over 8% of Drug Sales (Drug Channels)
• Flu shot makers gear up—and get creative—for a critical vaccination season (Fierce)
• The coronavirus pandemic is reigniting a fierce debate over compounded drugs (STAT)
• Takeda-partnered Evox signs up to $1.2B pact with Lilly; New liquid biopsy company launches with $12M Series A (Endpoints)
• Deciphering the Immune Response to Viral Infection (GEN)
• CSL Behring snaps up a closely-held biotech partner and its IL-6 drug — for transplant rejection (Endpoints)
• Not Every Label Change is a CBE Label Change (Drug & Device Law)
• Going where PROTACs can't, Versant unveils $50M bet on Carolyn Bertozzi's LYTAC tech — with a seasoned biotech exec at the helm (Endpoints)
• Regeneron joins $100M round for DNAnexus and its cloud-computing DNA software (Endpoints)
• ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS (Endpoints)
• ASCO In Brief: US FDA Looks At Safety Outcomes By Performance Status, Metastasis-Free Survival In Elderly Men (Pink Sheet)
• US FDA’s Project Facilitate Making Some Improvements To Expanded Access (Pink Sheet)
• GDUFA III May Be Opportunity For Proactive Pharmacovigilance Discussions (Pink Sheet)
• Cancer Drug Prices Inconsistent With Value Scores From NCCN Prescribing Tool (Pink Sheet)
• EU Approves Elanco's $7.6B Bayer Animal Biz Buy (Law360)
• WuXi Biologics inks lease agreement for 3rd U.S. facility in global expansion push (Fierce)
• Soleno's drug misses key goal in Prader-Willi trial (PharmaTimes)
• Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe (PharmaTimes)
• India Government may soon allow import of untested drugs under trial (Economic Times)

• Edwards wins approval to introduce Sapien 3 valve in China (MedtechDive)
• Personalized cancer test maker ArcherDX files $100M IPO (Fierce)
• GTX Medical wins FDA breakthrough device designation for targeted epidural spinal stimulation (MassDevice)
• Study: TAVR considered safe treatment for bicuspid valve disease (MassDevice)
• Dexcom lands CE Mark for G6 glucose monitor (MassDevice)

• Billions in COVID relief go to biggest hospital chains as smaller rivals await aid (Reuters)
• Amneal Pharmaceuticals LLC v. Almirall, LLC  (Fed. Cir. 2020) (Patent Docs)
• Bayer, Merck Beat Dr. Scholl's Buyer's Leg Amputation Suit (Law360)